Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alimera Sciences

Alimera Sciences
2003 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
ALIM STOCK SYMBOL
$0.36 SHARE PRICE (As of Tuesday Closing)
Description

Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. The product portfolio of the company includes ILUVIEN, which is developed to treat diabetic macular edema. In addition, to the activities related to the development of ILUVIEN, the group is also researching the safety and effectiveness of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors. Geographically it operates through the region of US and also it has its presence in the international market.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 6120 Windward Parkway
  • Suite 290
  • Alpharetta, GA 30005
  • United States

+1 (678) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Alimera Sciences’s full profile, request a free trial.

Alimera Sciences Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.32 - $1.21 $25.6M $0.36 $0.27 327K 71M

Alimera Sciences Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 119,014 106,341 169,540 139,055
Revenue 49,996 46,970 35,912 34,333
EBITDA (4,575) (8,856) (13,575) (25,057)
Net Income (12,499) (16,382) (22,001) (33,174)
Total Assets 50,242 54,108 59,924 70,229
Total Debt 38,707 38,414 34,752 33,549
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alimera Sciences Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Alimera Sciences‘s full profile, request access.

Request full access to PitchBook

Alimera Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Alimera Sciences‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Alimera Sciences Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Strongbridge Biopharma Corporate Backed or Acquired Trevose, PA 000 00000 00000000000 00000
000000 00000000 Formerly VC-backed Palo Alto, CA 00 00000 00000000 00000
000000 00000000000 Venture Capital-Backed San Diego, CA 000.00 00000000000 000.00
00000 000000000000 Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
To view this company’s complete list of competitors, request access »

Alimera Sciences Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Alimera Sciences‘s full profile, request access.

Request full access to PitchBook

Alimera Sciences Executive Team (14)

Name Title Board
Seat
Contact
Info
Richard Eiswirth Jr. Chief Executive Officer & Board Member
Daniel Myers Co-Founder, Chief Executive Officer & Board Member
Philip Jones Chief Financial Officer
Philip Ashman Ph.D Chief Operating Officer & Senior Vice President
David Holland Chief Marketing Officer & Founder

4 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

Alimera Sciences Board Members (17)

Name Representing Role Since Contact
Info
Calvin Roberts MD Self Board Member 000 0000
Daniel Myers Alimera Sciences Co-Founder, Chief Executive Officer & Board Member 000 0000
Garheng Kong MD Self Board Member 000 0000
James Largent Alimera Sciences Board Member 000 0000
Mark Brooks Self Board Member 000 0000

9 Former Board Members

You’re viewing 5 of 17 board members. Get the full list »